1. Home
  2. IRMD vs OMER Comparison

IRMD vs OMER Comparison

Compare IRMD & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IRMD

iRadimed Corporation

HOLD

Current Price

$81.95

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$18.47

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
OMER
Founded
1992
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
844.6M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
IRMD
OMER
Price
$81.95
$18.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$116.00
$32.50
AVG Volume (30 Days)
78.8K
2.3M
Earning Date
05-01-2026
05-14-2026
Dividend Yield
0.95%
N/A
EPS Growth
16.67
98.15
EPS
0.86
0.77
Revenue
$83,814,000.00
$29,868,000.00
Revenue This Year
$12.38
N/A
Revenue Next Year
$11.31
$233.22
P/E Ratio
$97.16
$25.18
Revenue Growth
14.43
N/A
52 Week Low
$67.84
$3.94
52 Week High
$107.90
$19.65

Technical Indicators

Market Signals
Indicator
IRMD
OMER
Relative Strength Index (RSI) 28.37 63.43
Support Level $76.95 $18.00
Resistance Level $88.93 $19.65
Average True Range (ATR) 2.13 0.83
MACD -0.24 -0.25
Stochastic Oscillator 5.03 35.76

Price Performance

Historical Comparison
IRMD
OMER

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: